Plant Name: Plantago depressa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HRH3; HRH4; HRH2; GPBAR1; HRH1; FFAR1; FFAR4; | |
| TSHR; NPSR1; | |
| PTPN1; PTPN2; CDC25B; | |
| BLM; GLA; TDP1; PLA2G1B; PKM; HSD17B1; GFER; AKR1B10; ALOX15; NOX4; ALDH1A1; USP2; TNKS; TNKS2; POLB; | |
| ACHE; | |
| GABRR2; | |
| CFTR; | |
| GSK3B; SYK; CDK6; FLT3; PIM1; PRKCA; CSNK2A1; | |
| AR; | |
| NR1I2; | |
| NR1H4; | |
| PPARA; PPARD; PPARG; | |
| ESR2; ESR1; | |
| KDM4E; | |
| MAOA; PTGS2; PTGS1; XDH; | |
| MMP12; MMP2; | |
| TLR2; | |
| HIF1A; TP53; NFKB1; | |
| ABCG2; ABCC1; | |
| RAB9A; NPC1; FABP3; FABP5; FABP2; FABP4; TTR; LMNA; MAPT; THPO; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| GABA-A receptor | GABRR2 | GABA receptor rho-2 subunit | P28476 | CHEMBL2375 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | HRH3 | Histamine H3 receptor | Q9Y5N1 | CHEMBL264 |
| Small molecule receptor (family A GPCR) | HRH4 | Histamine H4 receptor | Q9H3N8 | CHEMBL3759 |
| Small molecule receptor (family A GPCR) | HRH2 | Histamine H2 receptor | P25021 | CHEMBL1941 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | HRH1 | Histamine H1 receptor | P35367 | CHEMBL231 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.028E-10 | 1.790E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 8.664E-10 | 3.253E-07 | AR, BLM, CFTR, CYP1A1, CYP1B1, ESR1, FLT3, HRH1, NFKB1, NOX4, NPC1, PPARG, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.611E-09 | 5.481E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4, PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0004969; histamine receptor activity | 3.126E-09 | 9.768E-07 | HRH1, HRH2, HRH3, HRH4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.494E-08 | 3.614E-06 | CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.681E-08 | 3.935E-06 | CFTR, HIF1A, NPC1, NPSR1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.456E-08 | 5.456E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.516E-08 | 5.533E-06 | AR, ESR1, ESR2, NR1H4, NR1I2, PIM1, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 3.916E-08 | 7.764E-06 | AR, ESR1, ESR2, NR1H4, NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 4.203E-08 | 7.986E-06 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.325E-08 | 8.049E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.987E-08 | 1.204E-05 | AR, BLM, ESR1, ESR2, L3MBTL1, MMP12, MMP2, NR1H4, NR1I2, PPARA, PPARD, PPARG, PRKCA, PTPN1, TNKS, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.013E-07 | 1.647E-05 | CYP1A2, CYP2C19, CYP3A4, NR1I2 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.210E-07 | 1.883E-05 | ABCC1, ALOX15, PLA2G1B, SYK, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.959E-07 | 2.807E-05 | AR, ESR1, ESR2, NR1H4, NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.959E-07 | 2.807E-05 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, XDH |
| MF | Unclassified; | GO:0004872; receptor activity | 2.801E-07 | 3.934E-05 | AR, ESR1, ESR2, FFAR1, FFAR4, FLT3, GABRR2, GPBAR1, HRH1, HRH2, HRH3, HRH4, NPC1, NPSR1, NR1H4, NR1I2, PPARA, PPARD, PPARG, TLR2, TSHR |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 6.691E-07 | 8.621E-05 | FABP3, FFAR1, NR1H4, PPARG, PTGS2, TLR2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.115E-06 | 1.356E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 1.141E-06 | 1.380E-04 | AR, CDK6, CFTR, ESR1, FLT3, NFKB1, NPC1, NR1H4, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.193E-06 | 1.420E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.193E-06 | 1.420E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.521E-06 | 1.743E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.100E-06 | 2.345E-04 | CDK6, CFTR, HIF1A, NPC1, NPSR1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.493E-06 | 2.741E-04 | FABP2, FABP3, FABP4, FABP5 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 4.976E-06 | 5.016E-04 | ABCG2, ACHE, AKR1B10, AR, BLM, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, ESR1, ESR2, FABP4, FLT3, GFER, GLA, GSK3B, HIF1A, KDM4E, L3MBTL1, LMNA, MAOA, MAPT, MMP12, MMP2, NFKB1, NOX4, NPC1, PIM1, PKM, POLB, PPARA, PPARD, PPARG, PRKCA, PTGS1, PTGS2, PTPN1, PTPN2, RAB9A, SYK, TDP1, TLR2, TNKS, TNKS2, TP53, XDH |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 6.616E-06 | 6.342E-04 | ABCC1, ABCG2, NR1I2 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 9.072E-06 | 8.222E-04 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.039E-05 | 9.239E-04 | ABCG2, ACHE, BLM, CSNK2A1, ESR1, ESR2, FLT3, GLA, L3MBTL1, MAPT, NFKB1, PKM, PPARG, PTGS2, RAB9A, TP53, TTR, USP2, XDH |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.488E-05 | 1.241E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.488E-05 | 1.241E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0043255; regulation of carbohydrate biosynthetic process | 1.570E-05 | 1.295E-03 | GSK3B, HRH1, NFKB1, PPARA, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 1.669E-05 | 1.361E-03 | FABP3, PKM, PLA2G1B, PPARA, PPARG, TLR2 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 2.142E-05 | 1.684E-03 | ABCG2, ACHE, AR, BLM, FLT3, GLA, HIF1A, MAPT, NFKB1, PPARD, PPARG, PTGS2, TLR2, TP53, TTR, XDH |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 2.365E-05 | 1.853E-03 | ACHE, CSNK2A1, FLT3, L3MBTL1, MAPT, MMP12, PIM1, PKM, PPARA, PTPN1, PTPN2, SYK, TLR2, TSHR |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 2.620E-05 | 2.030E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 3.566E-05 | 2.651E-03 | FFAR1, HIF1A, NOX4, NR1H4, PPARG, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.676E-05 | 2.705E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 4.386E-05 | 3.183E-03 | AR, ESR1, ESR2, NFKB1, PLA2G1B, PPARG, TLR2 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 4.452E-05 | 3.185E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 4.452E-05 | 3.185E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.452E-05 | 3.185E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 4.452E-05 | 3.185E-03 | GPBAR1, NR1H4 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 4.668E-05 | 3.289E-03 | AKR1B10, ALDH1A1, ALOX15, AR, BLM, CDC25B, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GFER, GSK3B, HIF1A, HRH1, HSD17B1, LMNA, MAPT, NFKB1, PIM1, PKM, PLA2G1B, PPARG, PRKCA, PTPN1, PTPN2, RAB9A, SYK, TNKS, TNKS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.256E-05 | 3.645E-03 | HIF1A, LMNA, PPARD, PTGS2, TP53 |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 5.723E-05 | 3.906E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 6.021E-05 | 4.072E-03 | CYP19A1, NFKB1, PPARA, PPARG, SYK |
| BP | GO:0065007; biological regulation | GO:0055088; lipid homeostasis | 6.870E-05 | 4.589E-03 | FABP3, FABP4, NPC1, NR1H4, PPARG |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 8.881E-05 | 5.535E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 8.881E-05 | 5.535E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.881E-05 | 5.535E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 8.842E-05 | 5.535E-03 | AR, ESR1, GSK3B, PPARA, TP53 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 8.881E-05 | 5.535E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.881E-05 | 5.535E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 8.881E-05 | 5.535E-03 | ALDH1A1, AR |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 9.028E-05 | 5.585E-03 | AR, CDK6, CYP1B1, ESR1, GSK3B, HIF1A, L3MBTL1, MAPT, NR1H4, PIM1, PPARD, PPARG, PRKCA, PTGS2, PTPN2, SYK, THPO, TLR2, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.416E-05 | 5.792E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.073E-04 | 6.455E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.116E-04 | 6.694E-03 | BLM, CDK6, CFTR, CYP1B1, NFKB1, PTGS2, TP53 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.166E-04 | 6.937E-03 | CSNK2A1, ESR1, GSK3B, PPARA, PPARG, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.216E-04 | 7.215E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.371E-04 | 8.046E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 1.407E-04 | 8.212E-03 | CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 1.412E-04 | 8.213E-03 | ABCC1, ABCG2, ACHE, ALOX15, AR, CFTR, CSNK2A1, ESR1, FABP5, FFAR1, FFAR4, FLT3, GABRR2, GPBAR1, GSK3B, HRH1, HRH2, HRH3, HRH4, L3MBTL1, MAPT, MMP2, NPSR1, PIM1, PRKCA, PTPN1, PTPN2, RAB9A, SYK, TDP1, TLR2, TSHR |
| BP | GO:0051179; localization | GO:0015850; organic hydroxy compound transport | 1.459E-04 | 8.450E-03 | ABCG2, CFTR, NPC1, NR1H4, SYK |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.476E-04 | 8.460E-03 | PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.476E-04 | 8.460E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0051053; negative regulation of DNA metabolic process | 1.513E-04 | 8.601E-03 | BLM, PPARG, TNKS, TNKS2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.538E-04 | 8.698E-03 | CYP1B1, HIF1A, PTGS2 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.544E-04 | 8.708E-03 | AR, BLM, CDC25B, CDK6, CSNK2A1, ESR1, ESR2, FABP5, GSK3B, HIF1A, L3MBTL1, LMNA, NFKB1, NR1H4, NR1I2, PIM1, POLB, PPARA, PPARD, PPARG, PRKCA, PTPN2, TNKS, TP53, USP2 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.583E-04 | 8.862E-03 | BLM, GSK3B, HIF1A, TP53 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.718E-04 | 9.469E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.718E-04 | 9.469E-03 | MAPT, PTPN1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0032481; positive regulation of type I interferon production | 1.766E-04 | 9.686E-03 | MMP12, NFKB1, SYK, TLR2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.685E-08 | 2.443E-06 | AR; GSK3B; CDK6; FLT3; MMP2; PRKCA; PPARG; PTGS2; HIF1A; TP53; NFKB1; PPARD |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 7.017E-09 | 1.277E-06 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.866E-08 | 3.579E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.169E-08 | 3.579E-06 | PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.774E-07 | 2.358E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1; TLR2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.203E-06 | 3.128E-05 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.657E-06 | 3.769E-05 | ABCC1; CDK6; PIM1; CYP1B1; PRKCA; PTGS2; TP53; NFKB1; CDC25B |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.339E-07 | 2.307E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.548E-06 | 7.175E-05 | PLA2G1B; ALOX15; CYP2C19; PTGS2; PTGS1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.963E-06 | 7.213E-05 | MAOA; ALOX15; PRKCA; CYP2C19; PTGS2; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.717E-05 | 7.153E-04 | PLA2G1B; MAOA; ALOX15; PTGS2; CYP2C19; CYP3A4; CYP19A1; PTGS1; PKM; AKR1B10; HSD17B1; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.505E-05 | 2.490E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.198E-05 | 8.057E-04 | FLT3; PIM1; NFKB1; PPARD |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.142E-04 | 1.155E-03 | MMP2; PRKCA; TP53; HIF1A; ESR1; TLR2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.779E-05 | 8.057E-04 | FABP4; PTGS2; TSHR; PTGS1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.151E-05 | 9.889E-04 | GSK3B; PRKCA; TP53; ESR1; HIF1A |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.205E-04 | 1.155E-03 | POLB; CDK6; PKM; SYK; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.038E-04 | 1.155E-03 | CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.169E-04 | 1.155E-03 | PKM; FLT3; TP53; HIF1A |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.894E-04 | 1.951E-03 | GSK3B; CDK6; SYK; PRKCA; TP53; NFKB1; TLR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.215E-04 | 1.551E-03 | CDK6; PRKCA; TP53; NFKB1; TLR2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.947E-04 | 1.417E-03 | GSK3B; CSNK2A1; PRKCA; TP53; PPARD |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.547E-04 | 1.224E-03 | GSK3B; ESR1; NFKB1; ESR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.311E-04 | 1.193E-03 | MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.465E-04 | 1.212E-03 | NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.632E-04 | 1.238E-03 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.499E-04 | 2.196E-03 | GSK3B; AR; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.657E-04 | 3.321E-03 | MMP2; PIM1; PRKCA; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.069E-04 | 1.995E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 6.049E-04 | 3.336E-03 | GABRR2; HRH1; HRH3; HRH2; HRH4; TSHR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 9.735E-04 | 5.062E-03 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 4.138E-04 | 2.510E-03 | SYK; CSNK2A1; PTGS2; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 7.536E-04 | 4.034E-03 | PTPN1; GSK3B; PPARA; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.079E-03 | 5.453E-03 | ABCC1; PRKCA; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.577E-03 | 7.360E-03 | GSK3B; PPARA; TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.218E-03 | 5.834E-03 | GSK3B; CDK6; TP53; CDC25B |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.706E-03 | 1.073E-02 | PRKCA; MAPT; TP53; NFKB1; CDC25B |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.872E-03 | 8.519E-03 | CDK6; PRKCA; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.217E-03 | 5.834E-03 | CDK6; PRKCA; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.693E-03 | 1.817E-02 | FLT3; PPARG; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.609E-03 | 1.073E-02 | GSK3B; SYK; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 5.168E-03 | 1.935E-02 | CSNK2A1; TP53; NFKB1; TLR2 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.956E-03 | 8.684E-03 | CDK6; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.609E-03 | 1.073E-02 | CDK6; TP53; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.609E-03 | 1.073E-02 | PTGS2; NFKB1; TLR2 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.712E-03 | 1.073E-02 | HRH2; PRKCA; CFTR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.669E-03 | 2.167E-02 | PPARA; CFTR; NFKB1; TSHR |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.317E-03 | 1.935E-02 | PPARG; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.139E-03 | 2.108E-02 | MMP2; ESR1; ESR2 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 6.312E-03 | 2.127E-02 | PRKCA; NFKB1; TLR2 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 6.488E-03 | 2.147E-02 | GABRR2; PRKCA; PTGS2 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 5.637E-03 | 1.974E-02 | PLA2G1B; PRKCA; CFTR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.849E-03 | 2.187E-02 | PRKCA; HIF1A; NFKB1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 6.006E-04 | 3.336E-03 | ABCC1; CFTR; ABCG2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.039E-02 | 3.153E-02 | GSK3B; TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.263E-02 | 3.769E-02 | GSK3B; MAOA; PRKCA |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.571E-02 | 4.268E-02 | LMNA; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.343E-02 | 3.825E-02 | SYK; PPARG; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.609E-02 | 4.300E-02 | POLB; GSK3B; TP53; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.918E-02 | 4.847E-02 | GSK3B; PPARA; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.630E-02 | 4.300E-02 | GSK3B; TP53 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.813E-02 | 4.646E-02 | NFKB1; TLR2 |
| hsa05110 | Vibrio cholerae infection_Homo sapiens_hsa05110 | 1.571E-02 | 4.268E-02 | PRKCA; CFTR |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.813E-02 | 4.646E-02 | GSK3B; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.456E-02 | 4.078E-02 | MAOA; NFKB1 |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | 1.345E-02 | 3.825E-02 | PRKCA; ESR1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.035E-02 | 3.153E-02 | MMP2; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.291E-02 | 3.790E-02 | CYP3A4; XDH |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.276E-03 | 1.935E-02 | PPARG; TP53 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 1.035E-02 | 3.153E-02 | FABP2; PLA2G1B |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.639E-03 | 1.974E-02 | AKR1B10; GLA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.377E-04 | 1.194E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HRH3; HRH1; HRH1; HRH1; ACHE; CYP3A4; MAOA |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HRH3; HRH3; HRH2; AR; HRH1; ACHE; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM; PTGS1 |
| NA: NA | Perennial and seasonal allergic rhinitis | NA | HRH1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HRH3; ACHE; MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | HRH1; HRH1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | HRH4; SYK; MMP12; PLA2G1B; PTGS2; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | HRH2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HRH1; ACHE; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1; TLR2 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | HRH1; HRH1; PLA2G1B |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| NA: NA | Allergic disorders | NA | HRH1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HRH3; HRH3; GSK3B; ACHE; ACHE; ACHE; MAOA; PPARG; PPARG; PTGS2; MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Allergic skin disorders | L00-L99 | HRH1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | HRH1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HRH1; HRH1 |
| G00-G99: Diseases of the nervous system G00-G99 | Narcolepsy | G47.4 | HRH3 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PPARG; PTGS2; ABCC1; ABCC1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| NA: NA | Vasomotor rhinitis | NA | HRH1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| NA: NA | Respiratory allergies | NA | HRH1; HRH1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HRH3; MAOA |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2; PTGS1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HRH3; ESR1; NPSR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK; HRH1; HRH1; PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HRH3; HRH1; PPARD; PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obese insulin-resistant disorders | E11 | HRH3 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; HIF1A; SYK; HRH1; TP53; FLT3; FLT3; NFKB1; ACHE; ESR1; ESR1; TLR2; PIM1; MMP2; PTGS2; CDC25B; CSNK2A1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | HRH1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HRH3; HRH3 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | HRH3 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | HRH1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| K00-K95: Diseases of the digestive system | Acid-reflux disorders | K21 | HRH2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; MMP2; PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Common cold | NA | HRH1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; FLT3; TLR2; MMP2; PKM |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | HRH4; SYK; SYK; HRH1; MMP12; PLA2G1B; PTGS2 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | HRH3 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH3; HRH1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Morning sickness | NA | HRH1 |
| J00-J99: Diseases of the respiratory system | Seasonal and perennial allergic rhinitis and vasomotor rhinitis | J30 | HRH1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | HRH1; HRH1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | HRH4; SYK; PLA2G1B; PTGS2; PTGS2; PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | HRH3; HRH4; HRH1; HRH1; HRH1; HRH1; HRH1; PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | HRH1; HRH1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HRH3 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | HRH2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| H60-H95: Diseases of the ear and mastoid process | Vertigo meniere's disease | H81, H81.0, R42 | HRH1 |
| NA: NA | Vertigo's disease | NA | HRH1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| NA: NA | Vomiting | NA | HRH1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Excessive daytime sleepiness | F51.1, G47.1 | HRH3 |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HRH2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; NFKB1; PPARD; FFAR1; PPARG; PPARG; PTGS2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HRH3; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | HRH2; PTGS1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Urticaria | NA | HRH1; HRH1; HRH1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG; PTGS2; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| J00-J99: Diseases of the respiratory system | Hay fever | J30 | HRH1; HRH1; HRH1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HRH3; HRH3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; FFAR1; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1; TLR2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | HRH3 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | HRH1 |
| NA: NA | Coughs | NA | HRH1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HRH3; GPBAR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HRH1; MAOA |
| K00-K95: Diseases of the digestive system | Gastric ulcer | K25 | HRH2 |
| K00-K95: Diseases of the digestive system | Gastric secretory disorders | K30 | HRH2 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dry cough | R05 | HRH1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| NA: NA | Meniere's disease | NA | HRH1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | HRH2 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | HRH1 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HRH3; PPARD; MAPT |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| NA: NA | Hypersensitivity reactions | NA | HRH1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | HRH3; PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; MMP2; PTGS2 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; PPARD; NR1I2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; PTGS2; PTGS2; ABCC1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; MMP12 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| NA: NA | Itching | NA | HRH1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |